Cargando…
FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
Disclosure: M.D. Patil: None. S. Thosani: None. R.L. Bassett Jr: None. Z. Wang: None. T.A. Guise: None. Denosumab (dmab) is useful to treat conditions associated with increased bone resorption such as osteoporosis (OP), bone metastases (BM), hypercalcemia of malignancy and giant cell tumor of bone....
Autores principales: | Patil, Madhuri D, Thosani, Sonali, Bassett, Roland L, Wang, Zhongya, Guise, Theresa A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555234/ http://dx.doi.org/10.1210/jendso/bvad114.453 |
Ejemplares similares
-
PSAT225 Severe Hypercalcemia Following Denosumab Withdrawal in Giant Cell Tumor of Bone: A Double-edged Sword Treatment Paradigm?
por: Deepika, F N U, et al.
Publicado: (2022) -
SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019) -
Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021) -
SUN-513 Parathyromatosis: A Case of Stubborn Hypercalcemia Treated with Denosumab
por: Ventura, Kenilia, et al.
Publicado: (2019) -
MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)